The anti-CD20 chimaeric monoclonal antibody Rituximab has recently been shown to induce significant clinical response in a proportion of patients with refractory chronic graft-versus-host disease (cGVHD). We now report 38 patients, median age 48 years (22–61), receivingRituximab for refractory cGVHD, assessed for clinical response and survival. Median duration of cGVHD before Rituximab was 23 months(range 2–116), the median number of failed treatment lines was 3 (range 1 to >=6) and the median follow-up after Rituximab was 11 months (1–88). Overall response rate was 65%: skin 17/20(63%), mouth 10/21 (48%), eyes6/14 (43%), liver 3/12 (25%), lung 3/8 (37.5%), joints4/5, gut 3/4, thrombocytopaenia 2/3, vagina 0/2, pure red cell aplasia 0/1 and myasthenia gravis 1/1. During the study period 8/38 died: causes of death were cGVHD progression (n=3), disease relapse (n=1), infection (n=3), sudden death (n=1). Theactuarial 2 year survival is currently 76%. We confirm that Rituximab is effective in over 50% of patients with refractory cGVHD and may have a beneficial impact on survival.

Treatment of refractory chronic GVHD with Rituximab: a GITMO study / F., Zaja; A., Bacigalupo; F., Patriarca; M., Stanzani; M. T., VAN LINT; C., Fili; R., Scime; G., Milone; M., Falda; C., Vener; D., Laszlo; P. E., Alessandrino; Narni, Franco; S., Sica; A., Olivieri; A., Sperotto; A., Bosi; F., Bonifazi; R., Fanin. - In: BONE MARROW TRANSPLANTATION. - ISSN 0268-3369. - STAMPA. - 40:(2007), pp. 273-277. [10.1038/sj.bmt.1705725]

Treatment of refractory chronic GVHD with Rituximab: a GITMO study

NARNI, Franco;
2007

Abstract

The anti-CD20 chimaeric monoclonal antibody Rituximab has recently been shown to induce significant clinical response in a proportion of patients with refractory chronic graft-versus-host disease (cGVHD). We now report 38 patients, median age 48 years (22–61), receivingRituximab for refractory cGVHD, assessed for clinical response and survival. Median duration of cGVHD before Rituximab was 23 months(range 2–116), the median number of failed treatment lines was 3 (range 1 to >=6) and the median follow-up after Rituximab was 11 months (1–88). Overall response rate was 65%: skin 17/20(63%), mouth 10/21 (48%), eyes6/14 (43%), liver 3/12 (25%), lung 3/8 (37.5%), joints4/5, gut 3/4, thrombocytopaenia 2/3, vagina 0/2, pure red cell aplasia 0/1 and myasthenia gravis 1/1. During the study period 8/38 died: causes of death were cGVHD progression (n=3), disease relapse (n=1), infection (n=3), sudden death (n=1). Theactuarial 2 year survival is currently 76%. We confirm that Rituximab is effective in over 50% of patients with refractory cGVHD and may have a beneficial impact on survival.
2007
40
273
277
Treatment of refractory chronic GVHD with Rituximab: a GITMO study / F., Zaja; A., Bacigalupo; F., Patriarca; M., Stanzani; M. T., VAN LINT; C., Fili; R., Scime; G., Milone; M., Falda; C., Vener; D., Laszlo; P. E., Alessandrino; Narni, Franco; S., Sica; A., Olivieri; A., Sperotto; A., Bosi; F., Bonifazi; R., Fanin. - In: BONE MARROW TRANSPLANTATION. - ISSN 0268-3369. - STAMPA. - 40:(2007), pp. 273-277. [10.1038/sj.bmt.1705725]
F., Zaja; A., Bacigalupo; F., Patriarca; M., Stanzani; M. T., VAN LINT; C., Fili; R., Scime; G., Milone; M., Falda; C., Vener; D., Laszlo; P. E., Alessandrino; Narni, Franco; S., Sica; A., Olivieri; A., Sperotto; A., Bosi; F., Bonifazi; R., Fanin
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/610269
Citazioni
  • ???jsp.display-item.citation.pmc??? 47
  • Scopus 167
  • ???jsp.display-item.citation.isi??? 145
social impact